Telomerase inhibition using azidothymidine in the HT-29 colon cancer cell line

被引:53
作者
Brown, T
Sigurdson, E
Rogatko, A
Broccoli, D
机构
[1] Fox Chase Canc Ctr, Dept Surg Oncol, Philadelphia, PA 19111 USA
[2] Fox Chase Canc Ctr, Dept Biostat, Philadelphia, PA 19111 USA
[3] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA
关键词
telomerase; AZT; HT-29 colon cancer cell line; telomere;
D O I
10.1245/ASO.2003.03.032
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: We investigated the effects of telomerase inhibition by using the reverse transcriptase inhibitor azidothymidine (AZT) in the human colorectal cancer cell line HT-29 in the presence and absence of 5-fluorouracil (5-FU). Methods: HT-29 cells were cultured in the presence of AZT. Telomerase activity was measured by using the telomerase repeat amplification protocol. Telomere length was determined by Southern analysis. The colorimetric microtiter assay was performed to determine the cytotoxic effects of AZT, alone and in combination with 5-FU. Results: The presence of 3'-azido-3'-deoxythymidine triphosphate, (AZT-TP) effectively inhibited telomerase extracted from HT-29 cells. HT-29 cells cultured with 125 muM of AZT underwent fewer total population doublings over 91 days. Southern analysis revealed that telomere attrition occurred within this period. Exposure to 125 muM of AZT resulted in slightly reduced viability (10%) of HT-29 cells. However, the presence of AZT increased 5-FU cytotoxicity, suggesting that the effects of these two drugs are synergistic. Conclusions: The data are consistent with telomerase inhibition having growth-inhibitory effects in addition to those predicted to accompany loss of telomere function. Further studies using specific small-molecule inhibitors will confirm whether the growth-inhibitory and 5-FU-sensitivity effects seen here are a direct result of telomerase inhibition.
引用
收藏
页码:910 / 915
页数:6
相关论文
共 31 条
[11]   Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes [J].
González-Suárez, E ;
Samper, E ;
Ramírez, A ;
Flores, JM ;
Martín-Caballero, J ;
Jorcano, JL ;
Blasco, MA .
EMBO JOURNAL, 2001, 20 (11) :2619-2630
[12]   Viral and cellular factors for resistance against antiretroviral agents [J].
Gröschel, B ;
Cinatl, J ;
Cinatl, J .
INTERVIROLOGY, 1997, 40 (5-6) :400-407
[13]   Inhibition of telomerase limits the growth of human cancer cells [J].
Hahn, WC ;
Stewart, SA ;
Brooks, MW ;
York, SG ;
Eaton, E ;
Kurachi, A ;
Beijersbergen, RL ;
Knoll, JHM ;
Meyerson, M ;
Weinberg, RA .
NATURE MEDICINE, 1999, 5 (10) :1164-1170
[14]   Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends [J].
Howe, HL ;
Wingo, PA ;
Thun, MJ ;
Ries, LAG ;
Rosenberg, HM ;
Feigal, EG ;
Edwards, BK .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (11) :824-842
[15]   DECREASED THYMIDINE KINASE LEVELS IN PERIPHERAL-BLOOD CELLS FROM HIV-SEROPOSITIVE INDIVIDUALS - IMPLICATIONS FOR ZIDOVUDINE METABOLISM [J].
JACOBSSON, B ;
BRITTON, S ;
HE, QM ;
KARLSSON, A ;
ERIKSSON, S .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1995, 11 (07) :805-811
[16]   Telomerase inhibitors: targeting the vulnerable end of cancer? [J].
Kelland, LR .
ANTI-CANCER DRUGS, 2000, 11 (07) :503-513
[17]   SPECIFIC ASSOCIATION OF HUMAN TELOMERASE ACTIVITY WITH IMMORTAL CELLS AND CANCER [J].
KIM, NW ;
PIATYSZEK, MA ;
PROWSE, KR ;
HARLEY, CB ;
WEST, MD ;
HO, PLC ;
COVIELLO, GM ;
WRIGHT, WE ;
WEINRICH, SL ;
SHAY, JW .
SCIENCE, 1994, 266 (5193) :2011-2015
[18]   MITOCHONDRIAL TOXICITY OF ANTIVIRAL DRUGS [J].
LEWIS, W ;
DALAKAS, MC .
NATURE MEDICINE, 1995, 1 (05) :417-422
[19]  
Longford NT., 1993, RANDOM COEFFICIENT M
[20]   Structure, subnuclear distribution, and nuclear matrix association of the mammalian telomeric complex [J].
Luderus, ME ;
vanSteensel, B ;
Chong, L ;
Sibon, OCM ;
Cremers, FFM ;
deLange, T .
JOURNAL OF CELL BIOLOGY, 1996, 135 (04) :867-881